Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.53 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | CCKBR | P32239 | 6/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037495 | 0.94 | MC4R (0.52) | IL23RMC4RCCKBRCTSLCTSS | |
| SCHEMBL10419744 | 0.90 | C5AR1 (0.51) | MC4RGLP1RCTSLCTSSCTSK | |
| SCHEMBL30264577 | 0.89 | MC4R (0.52) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL31016486 | 0.89 | CTSL (0.55) | IL23RMC4RCCKBRGLP1RCTSL | |
| SCHEMBL30510367 | 0.88 | MC4R (0.52) | MC4RCCKBRCTSLCTSSCTSK | |
| SCHEMBL30464987 | 0.88 | IL23R (0.57) | IL23RMC4RCCKBRCCKAROPRD1 | |
| SCHEMBL30599231 | 0.87 | QRFPR (0.47) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL14117706 | 0.87 | MC4R (0.55) | IL23RMC4RCCKBRCTSLCTSS | |
| SCHEMBL21146569 | 0.87 | IL23R (0.66) | IL23RMC4R | |
| SCHEMBL31016482 | 0.86 | CTSL (0.54) | IL23RGLP1RCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | claimed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | claimed |
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | IL23R 466/4885MC4R 2/4885CCKBR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.